全球核醫學市場（2023-2030）：規模、份額、按產品類型（診斷（SPECT/PECT）/治療（ALPHA發射器/BETA發射器））和應用（心髒病/神經病學/腫瘤學）預測的增長分析

全球核醫學市場將從2021年的81億美元和2022年的89億美元增長到2030年的244億美元，預測期內復合年增長率為13%。預計

由於強大的產品線和旨在增加獲得這些技術的政府支持舉措，核醫學市場正在不斷增長。 儘管受到 COVID-19 的影響，在基本藥物生產中發揮重要作用的核反應堆仍在繼續運行，並採取了嚴格的安全措施。 前列腺癌是一個主要問題，尤其是老年男性，最近 Pluvicto (177Lu-PSMA-617) 被美國 FDA 批准用於治療轉移性前列腺癌。 這進一步凸顯了核醫學的進步。

癌症和心血管疾病的發病率和患病率上升是推動核醫學市場擴張的主要因素。 這些疾病往往可以通過早期發現和早期治療來預防，而核醫學發揮著重要作用。 根據世界衛生組織 (WHO) 的數據，癌症是 2020 年的首要死因，預計到 2025 年癌症病例數還會增加。 同樣，心血管疾病佔 2019 年全球死亡人數的大部分，預計到 2030 年將進一步增加。 核醫學在這些疾病的診斷和治療中的應用將帶來顯著的市場增長。 核成像技術（尤其是 PET/PET-CT）的技術進步已將其應用範圍從腫瘤學擴展到心髒病學、神經學和傳染病檢測等領域。 人們越來越認識到早期診斷和改善疾病管理的積極影響，進一步推動市場增長，導致 PET 和 SPECT 手術數量增加。

在本報告中，我們調查了全球核醫學市場，並提供了市場概況、市場各種影響因素分析、技術和創新趨勢、法律和監管環境、市場規模的轉變和預測、各種細分市場和地區。編制了單獨的細分、競爭格局、主要參與者的概況等。

內容

執行摘要

調查方法

母公司市場分析

• 市場概況
• 市場規模
• 市場動態
  • 驅動程序
  • 機會
  • 制約因素
  • 任務

主要市場洞察

• 技術分析
• 價格分析
• 供應鏈分析
• 價值鏈分析
• 市場生態系統
• 知識產權分析
• 貿易分析
• 啟動分析
• 原材料分析
• 創新矩陣
• 管道產品分析
• 宏觀經濟指標
• 主要投資分析
• 關鍵成功因素
• 爭用程度

市場動態與展望

• 市場動態
  • 驅動程序
  • 機會
  • 制約因素
  • 任務
• 監管狀況
• 波特的分析
• Skyquest 對未來顛覆的特殊洞察

按產品類型劃分的全球核醫學市場

• 市場概況
• 診斷（SPECT/PECT）
• 處理（ALPHA發射器/BETA發射器）
• 近距離放射治療

全球核醫學市場：按應用分類

• 市場概況
• 心髒病學和神經病學系
• 腫瘤
• 甲狀腺
• 淋巴瘤
• 骨轉移
• 內分泌腫瘤
• 其他

全球核醫學市場：按地區

• 市場概況
• 北美
• 歐洲
• 亞太地區
• 拉丁美洲
• 中東和非洲

競爭格局

• 排名前 5 名的公司比較
• 主要公司的市場定位
• 各大公司的招聘策略
• 關鍵成功策略
• 近期市場活動
• 主要公司的市場份額

主要公司簡介

• GE Healthcare
• Siemens Healthineers
• Philips Healthcare
• Curium Pharma
• Cardinal Health
• Bracco Imaging
• Eckert &Ziegler
• Lantheus Medical Imaging
• Jubilant Life Sciences
• Nordion Inc.
• IBA Molecular
• Advanced Accelerator Applications (AAA)
• Progenics Pharmaceuticals
• Norgine BV
• FUJIFILM Holdings Corporation
• Bayer Healthcare
• Theragnostics
• RadioMedix Inc.
• Ion Beam Applications SA (IBA)
• Novartis AG

Global Nuclear Medicine Market size was valued at USD 8.1 billion in 2021 and is poised to grow from USD 8.9 billion in 2022 to USD 24.4 billion by 2030, growing at a CAGR of 13% in the forecast period (2023-2030).

Nuclear medicine is a specialized field within radiology that utilizes small amounts of radioactive materials to examine organ structure and function. It combines various disciplines such as chemistry, physics, mathematics, computer technology, and medicine. This branch of radiology is particularly valuable in diagnosing and treating diseases at early stages, such as thyroid cancer. While standard X-rays have limitations in visualizing soft tissues, nuclear medicine imaging enables clearer visualization of organs and tissues. The market for nuclear medicine is experiencing growth due to a robust product pipeline and supportive government initiatives aimed at enhancing access to these technologies. Despite the impact of the COVID-19 pandemic, nuclear reactors, which play a critical role in producing essential medicines, have continued operations with stringent safety measures. Prostate cancer is a significant concern, with high incidence rates, particularly among older men. The recent approval of Pluvicto (177Lu-PSMA-617) by the U.S. FDA for the treatment of metastatic prostate cancer further underscores the advancements in nuclear medicine.

Segments covered in this report:

Global nuclear medicine market has been segmented based on product type, application, end use, procedure, and region. Based on product type, global nuclear medicine market are further sub-segmented into diagnostic (SPECT and PET), therapeutic (alpha emitters and beta emitters), and brachytherapy. On the basis of application, global nuclear medicine market is segmented into cardiology neurology, oncology, thyroid, lymphoma, bone metastasis, endocrine tumour, and others. According to end use, global nuclear medicine market is segmented into hospitals & clinics, diagnostic centers and others. By procedure, the market is segmented into central nervous system, endocrine, skeletal, gastrointestinal, genito-urinary, pulmonary. By region, the market is segmented into North America, Europe, Asia Pacific, Latin America, and MEA.

Driver

The increasing incidence and prevalence of cancer and cardiovascular disease are key factors driving the expansion of the nuclear medicine market. These diseases can often be prevented through early detection and treatment, where nuclear medicine plays a crucial role. According to the World Health Organization (WHO), cancer was the leading cause of death in 2020, with an expected rise in new cases worldwide by 2025. Similarly, cardiovascular disease accounted for a significant number of global deaths in 2019, with projections indicating a further increase by 2030. The utilization of nuclear medicine in diagnosing and treating these conditions positions it for significant market growth. Technological advancements in nuclear imaging modalities, particularly PET/PET-CT, have expanded its applications beyond oncology to areas like cardiology, neurology, and infection detection. The increased awareness of the positive impact of early diagnosis and improved disease management further drives market growth, resulting in a rise in PET and SPECT procedures.

Restraint

The growth of the nuclear medicine imaging market is expected to be restrained in the coming years due to the increasing adoption of alternative diagnostic options such as MRI and CT scans. These alternatives are more cost-effective compared to nuclear medicines, leading to their greater use, especially in developing nations. Moreover, reimbursement policies favor the utilization of MRI and CT scans, further hindering the market for nuclear medicine. Additionally, the high cost associated with nuclear imaging systems and procedures, along with the extensive use of CT and MRI scans annually, pose a risk to the volume of PET-CT procedures.

Key Market Trend

The market for nuclear medicine therapies is witnessing a focus on development by companies, driven by the clinical benefits of this treatment option compared to others. The demand for nuclear medicine therapies is expected to rise globally, supported by the positive outcomes observed in the treatment of cancer and other disorders. This is particularly significant in countries with a high cancer burden. For instance, Curium received FDA approval to initiate a Phase-III trial for lutetium Lu 177 PSMA I&T, a radiopharmaceutical targeting Prostate-Specific Membrane Antigen (PSMA). Many market participants are also actively developing new therapeutic products for various medical conditions, contributing to the growth of the market.

Table of Contents

Executive Summary

• Market Overview
• Wheel of Fortune

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Parent Market Analysis

• Market Overview
• Market Size
• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges

Key Market Insights

• Technology Analysis
• Pricing Analysis
• Supply Chain Analysis
• Value Chain Analysis
• Ecosystem of the Market
• IP Analysis
• Trade Analysis
• Startup Analysis
• Raw Material Analysis
• Innovation Matrix
• Pipeline Product Analysis
• Macroeconomic Indicators
• Top Investment Analysis
• Key Success Factor
• Degree of Competition

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Regulatory Landscape
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers
• Skyquest Special Insights on Future Disruptions
  • Political Impact
  • Economic Impact
  • Social Impact
  • Technical Impact
  • Environmental Impact
  • Legal Impact

Global Nuclear Medicine Market by Product type

• Market Overview
• Diagnostic (SPECT AND PECT)
• Therapeutic (Alpha Emitters and Beta Emitters)
• Brachytherapy

Global Nuclear Medicine Market by Application

• Market Overview
• Cardiology Neurology
• Oncology
• Thyroid
• Lymphoma
• Bone Metastasis
• Endocrine Tumor
• OthersSegmentEnd-userSub-SegmentsHospitals & Clinics
• Diagnostic Centers and OthersSegmentProcedureSub-SegmentsCentral Nervous System
• Endocrine
• Skeletal
• Gastrointestinal
• Genito-urinary
• Pulmonary

Global Nuclear Medicine Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2021
• Strategies Adopted by Key Market Players
• Top Winning Strategies
  • By Development
  • By Company
  • By Year
• Recent Activities in the Market
• Key Companies Market Share (%), 2021

Key Company Profiles

• GE Healthcare
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Philips Healthcare
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Curium Pharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cardinal Health
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bracco Imaging
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eckert & Ziegler
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lantheus Medical Imaging
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Jubilant Life Sciences
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nordion Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• IBA Molecular
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Advanced Accelerator Applications (AAA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Progenics Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Norgine B.V.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• FUJIFILM Holdings Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer Healthcare
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Theragnostics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• RadioMedix Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ion Beam Applications S.A. (IBA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments